US FDA Corrects Errors, Limits PDUFA Application Fee Increase

The agency used a 10-year average with updated figures to calculate the FY 2025 PDUFA application fee and limit the impact of submission volatility, but still allowed GDUFA and BsUFA fees to skyrocket.

error
The FDA did not account for fee refunds and waivers in its FY 2023 and FY 2024 FAE calculations. • Source: Shutterstock

Prescription drug application user fees will increase again in fiscal year 2025, although not as much as the previous year, while similar charges for generics and biosimilars will spike.

Key Takeaways
  • PDUFA, GDUFA and BsUFA application fees are set to increase again in FY 2025.

PDUFA fees for applications requiring clinical data will jump 6.5% to $4.31m in the upcoming fiscal year compared to FY...

More from User Fees

More from Pathways & Standards